Stuart Mitchell Presents Novuson at LSI USA '23

Transcription

Stuart Mitchell  0:00  

Hi I'm Stuart Mitchell the CEO and founder of Novuson where we are clearing the way for safer surgeries novice on has developed the next generation of Advanced Energy surgical devices that are safer and more precisely current technologies, making save surgeries faster and more efficient without risking the health and safety of the patients or the healthcare team. Our executive management team has experience in business technology finance product commercialization, Jean and myself have successfully built and sold a veterinary specialty practice. Marco Dara has developed products and might launch them and commercialize them. Eric course and or Derek Roseann has experience in clinical trials and device commercialization. Before I get into Novuson this technology, I'm going to hit some of our highlights of milestones we have for working prototypes, all successful proof of concept. We are ready for regulatory clearance pending our validation studies. This is the last step before product commercialization. We've used our technology and over 1000 studies, many of them performed by surgeons, we have 14 patents. We have pre commercialization revenue. By integrating our technology with a surgical robotic solution. We've raised 10 million in funding to date. About 30% of that is non dilutive, we have two strategic partners. And we have one post commercialization customer wait waiting for us to commercialize our devices. Our medical advisors consists of surgeons in robotic surgery and other surgical specialties. That a smaller device, and you can see that they are just as passionate about our technology as we are. myself. I have a PhD in bioengineering. I've worked with surgeon collaborators, the government agencies and corporations for about 20 years developing devices and technology to improve disease conditions or to improve a health care. And I've used many of the energy devices that are currently on the market in my studies. And the interesting thing is, is that while we were doing our studies, a lot of the officers around us would come and complain about this mount smell and the smoke from our surgical devices. In a discussion with my surgical collaborators, they all indicate that the devices make smoke, the cause problem, they cause irritation, and it's a concern that they're risking their health and the health of their patients. And this is really why we started Novus on because we felt we can make a better solution we have a solution that doesn't emit smoke. This is what surgeons see when they're using the current technology in the laparoscopic procedure smoke. This smoke is caused because the current device is burned and char tissue. Both the radiofrequency devices and the harmonic devices burn and char the tissue obscuring the surgeons field of vision. Over 30% of surgeries have complications 50% of those are considered avoidable. Three quarters are due to technical errors. Complications cost the hospital system $215 billion per year in the US. And if you think about it, if the surgeons cannot clearly see what they're operating on the chance for errors, it's increased many fold. But there's more. The smoke is at carcinogenic. The protective equipment that the surgeons use doesn't protect them from the toxic acids, the viruses or the biological materials contained in the smoke. Studies show that the daily exposure to surgical smoke is equivalent to smoking 27 to 30, unfiltered cigarettes, putting both the surgeons and the patient's health at risk. And really this is why we we developed Novuson is we can make a better solution we do make a better solution. Novice on makes a alternative energy device that is cleaner and safer than current technologies on the market. This is our technology and using an animal model. As you can see, we just clamp it on the tissue gets activated. It cauterizes right to the tissue and it cuts the tissue. There's no burning and there's no charge and Novuson does things just a little differently. What we do is we use ultrasound energy and we cauterize or weld the tissue from the inside out, and we use ultrasound to cut the tissue. using ultrasound is more efficient than radiofrequency devices, which basically use electricity to burn through the tissue, cauterize it or the harmonic devices, which use friction to burn to the tissue. Our technology is ergonomically designed, it's easy to use. Basically surgeons just place a clamp and on the tissue pull the trigger it seals it divides the tissue, the tissues well didn't cut it. So just the clear cut rapid saved from precise surgeries. The benefits are clear. We can be used in any soft tissue, we can actually use our technology in complete liquid solution or even in blood. We're smaller in diameter, which makes us more precise, more control or safer. The only seat we divide are on the market that can go into robotic and endoscopic surgery, which leaves us open for a wide range of clinical applications. compared to the competitors, the two main competitors, the ligature and the harmonic ace. We have no smoke emissions we can be used and blood or fluids were safer, more precise, and we have the lowest thermal spread in industry. Just a little deeper dive on our milestones. Since 2014 are now we have pre commercial revenue, commercialization revenue from a robotics collaboration. We've raised about 10 million in funding, and we're really close to commercialization on that funding level. We've met with the FDA we had. We've signed strategic investors, we've done our pre commercialization our products ready for commercialization. It's a $6.4 billion global global to total addressable market, there's 410 million surgical procedures that can be performed. In minimally invasive general robotic or endoscopic surgery. Novuson's technology is the only technology that can be integrated in all these platforms. We're initially going to focus on the US market which gives us about a $2.6 billion segment of the market. Notice on has two main revenue sources. Our first is through the licensing agreement, or the contract with the robotics This is a service contract which will go into licensing and royalty agreements and whatever what I've shown here are other revenue streams from direct sales from our razor razor blade business model. The handsets are Disposable single use the control console is a capital equipment that gets placed in surgical suites. Sales are predicated on how many surgeries and how many surgical suites we project 12 million in funding in four years. Novuson builds our technology in house for the usability and regulatory studies. We're currently working on the robotics collaboration once we finalize the first phase of that will do direct sales to ambulatory surgical centers and follow that with distribution. This is our product pipeline. We're working on the laparoscopic and robotic. Everything we do, they're going to general surgery and from there we go into endoscopy comm perioperative bleeding. We currently have a preferred equity round open we've raised 10 million to date. We're using this money to bring our three millimeter device to market which is nine to 12 months what we project surgical smoke is a problem. Novuson's technology does not cause smoke. We're the only three millimeter diameter sealer divider, the safest device on the market. One step from commercialization. We have pre commercialization revenue. We have strategic partners, we've raised non diluted funding, and we have a very strong enthusiastic team ready to take us to market. Thank you